Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: implications of imatinib mesylate.

World journal of gastroenterology - 21 Jun 2006

Yeh Chun-Nan, Chen Tsung-Wen, Wu Ting-Jung, Hsueh Swei, Jan Yi-Yin

Abstract excerpt

AIM: To examine the impact of imatinib mesylate (Glivec) on patient survival and response and its safety, and the correlation of the response rate with the kit gene mutation status. METHODS: Thirty-three of 74 (44.6%) small bowel gastrointestinal stromal tumor (GIST) patients who developed recurrence after curative resection and not treated with Glivec were classified as group A patients. Twenty-two advanced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Gastrointestinal Stromal Tumors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Intestinal Neoplasms

Share to Piperazines

Share to Platelet-Derived Growth Factor

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 16773696
DOI: 10.3748/wjg.v12.i23.3760
PMCID: PMC4087472

Genes

PDGFRA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: implications of imatinib mesylate.PMID 16773696Read ↗

Imatinib mesilate for the treatment of gastrointestinal stromal tumour.Semantic proximity Read ↗

The outcome of targeted therapy in advanced gastrointestinal stromal tumors (GIST) with non-exon 11 KIT mutations.Semantic proximity Read ↗

The GIST of Advances in Treatment of Advanced Gastrointestinal Stromal Tumor.Semantic proximity Read ↗

Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.Semantic proximity Read ↗

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.Semantic proximity Read ↗

Molecular Advances in the Treatment of Advanced Gastrointestinal Stromal Tumor.Semantic proximity Read ↗

Recent advances in the management of gastrointestinal stromal tumors.Semantic proximity Read ↗

Targeted therapy and personalized medicine in gastrointestinal stromal tumors: drug resistance, mechanisms, and treatment strategiesSemantic proximity Read ↗

Targeted Therapy for Advanced Gastrointestinal Stromal Tumors: Evolution and Future Directions.Semantic proximity Read ↗

Efficacy evaluation of imatinib treatment in patients with gastrointestinal stromal tumors: a meta-analysis.Semantic proximity Read ↗

Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.Semantic proximity Read ↗

The role of KIT in the management of patients with gastrointestinal stromal tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.